| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 1,921 | 2,103 | 2,067 | 2,083 | 2,249 | 2,336 | 2,320 | 2,674 | 2,526 | 2,374 | 2,454 | 2,692 |
| Expenses | 1,470 | 1,586 | 1,617 | 1,468 | 1,516 | 1,579 | 1,526 | 1,775 | 1,616 | 1,558 | 1,541 | 1,549 |
| EBITDA | 450 | 517 | 450 | 615 | 733 | 757 | 793 | 898 | 910 | 816 | 913 | 1,143 |
| Operating Profit % | 21 % | 21 % | 18 % | 25 % | 27 % | 27 % | 32 % | 32 % | 33 % | 29 % | 32 % | 33 % |
| Depreciation | 131 | 124 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 | 61 |
| Interest | 1 | 1 | 1 | 0 | 1 | 11 | 15 | 11 | 13 | 15 | 8 | 10 |
| Profit Before Tax | 238 | 402 | 517 | 548 | 660 | 643 | 669 | 773 | 824 | 746 | 1,016 | 1,073 |
| Tax | 138 | 179 | 180 | 188 | 231 | 133 | 171 | 160 | 200 | 195 | 249 | 277 |
| Net Profit | 100 | 223 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 809 |
| EPS in ₹ | 15.26 | 66.66 | 73.61 | 78.70 | 93.78 | 111.28 | 108.77 | 133.89 | 136.38 | 119.22 | 136.46 | 176.80 |
Pfizer
Pfizer
5,181.50
-27.50
(-0.53%)
Key Fundamentals
Market Cap
23,830.00 Cr
EPS
136.46
PE Ratio
29.46
Dividend Yield
3.17 %
Industry
Healthcare 52 Week High
5,993.00
52 Week Low
3,701.00
PB Ratio
5.65
Debt to Equity
0.01
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from3 analysts
Actual
Company News
View All News
Pfizer CEO Announces Domestic Medicine Production Focus, Receives Three-Year Tariff Grace Period
Sep 30, 2025
Sep 30, 2025Pfizer Inc's CEO confirmed the company will concentrate on producing medicines domestically in the United States. The pharmaceutical company has been granted a three-year grace period from 232 tariffs, which will allow it to avoid these trade-related costs during this transition period.
Pfizer Inc announced a $70 billion investment focused on research and domestic production. The pharmaceutical company also revealed plans to launch a direct-to-consumer drug sales platform called Trumprx that will offer discounted medications.
Pfizer Reports Strong Q1 Results with 27% Jump in Net ProfitAug 13, 2025
Pfizer delivered robust quarterly performance with net profit rising to 1.9 billion rupees from 1.5 billion rupees year-over-year. Revenue grew to 6 billion rupees compared to 5.6 billion rupees in the same period last year. The company's EBITDA increased to 2.1 billion rupees from 1.8 billion rupees, while EBITDA margin expanded to 34.83% from 31.62% year-over-year, indicating improved operational efficiency.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,706.40 | #1 4,05,655.60 | 39.00 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.65 | |
6,804.00 | 1,78,872.70 | 77.66 | 9,712.00 | 18.67 | 2,191 | 26.74 | 71.75 | |
1,511.50 | 1,21,268.10 | 22.32 | 28,409.50 | 7.12 | 5,291 | 3.71 | 41.32 | |
3,628.30 | 1,20,490.00 | 60.16 | 11,539.40 | 6.99 | 1,911 | 19.91 | 57.41 | |
1,196.00 | 99,953.30 | #1 17.42 | 33,741.20 | 16.73 | 5,725 | -0.38 | 33.50 | |
2,399.50 | 98,401.60 | 51.41 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.28 | |
981.05 | 98,052.50 | 20.81 | 23,511.00 | 18.55 | 4,615 | 2.60 | 43.10 | |
1,983.80 | 89,683.70 | 24.10 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 57.46 | |
1,158.60 | 66,147.50 | 19.68 | 32,345.60 | 9.43 | 3,484 | -10.24 | 66.97 | |
5,628.50 | 65,838.50 | 28.22 | 13,458.30 | 3.70 | 2,216 | 21.39 | 62.20 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
3.37 %
Net Income Growth
39.23 %
Cash Flow Change
156.87 %
ROE
18.72 %
ROCE
14.12 %
EBITDA Margin (Avg.)
8.20 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 2,612 | 2,914 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 |
| Fixed Assets | 944 | 895 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 724 |
| Current Assets | 1,253 | 1,630 | 2,051 | 2,417 | 2,715 | 3,048 | 1,925 | 2,397 | 2,493 | 2,738 | 3,513 |
| Capital Work in Progress | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 8 |
| Investments | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 1,655 | 2,011 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 4,180 |
| Total Liabilities | 2,612 | 2,914 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,911 |
| Current Liabilities | 606 | 759 | 780 | 954 | 892 | 873 | 774 | 853 | 657 | 547 | 570 |
| Non Current Liabilities | 32 | 36 | 62 | 52 | 37 | 137 | 99 | 183 | 136 | 87 | 124 |
| Total Equity | 1,973 | 2,118 | 2,419 | 2,683 | 3,011 | 3,396 | 2,393 | 2,864 | 3,207 | 3,596 | 4,217 |
| Reserve & Surplus | 1,927 | 2,072 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 4,172 |
| Share Capital | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 181 | -417 | -4 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 | 383 |
| Investing Activities | 68 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | -71 |
| Operating Activities | 114 | 346 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | 660 |
| Financing Activities | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | -205 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % | 63.92 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.82 % | 0.00 % | 3.33 % | 3.22 % | 3.54 % | 2.75 % | 2.18 % | 2.39 % | 2.60 % |
| DIIs | 13.08 % | 8.98 % | 8.98 % | 8.84 % | 8.57 % | 7.91 % | 14.85 % | 14.93 % | 14.89 % | 14.89 % | 15.01 % | 15.15 % | 15.33 % | 15.84 % | 16.03 % | 16.79 % | 17.10 % | 17.23 % | 17.10 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 15.03 % | 14.11 % | 14.11 % | 14.25 % | 14.19 % | 14.08 % | 13.94 % | 13.71 % | 13.70 % | 13.69 % | 13.61 % | 13.21 % | 12.90 % | 12.55 % | 12.15 % | 12.12 % | 12.34 % | 12.02 % | 12.08 % |
| Others | 7.97 % | 12.98 % | 12.98 % | 12.99 % | 13.32 % | 14.08 % | 7.29 % | 7.43 % | 7.49 % | 7.50 % | 4.64 % | 7.72 % | 4.52 % | 4.46 % | 4.35 % | 4.41 % | 4.45 % | 4.43 % | 4.29 % |
| No of Share Holders | 1,45,980 | 1,21,153 | 1,21,153 | 1,26,808 | 1,25,287 | 1,23,449 | 1,22,028 | 1,17,950 | 1,17,194 | 1,15,988 | 1,16,948 | 1,12,456 | 1,09,214 | 1,06,098 | 98,824 | 1,05,015 | 1,08,261 | 1,03,222 | 1,03,480 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 20 | 20 | 22.5 | 330 | 35 | 35 | 70 | 35 | 165 |
| Dividend Yield (%) | 0.00 | 0.92 | 0.6 | 0.56 | 7.29 | 0.8 | 1 | 1.67 | 0.87 | 3.17 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Aug 2021 |  Dividend | ₹ 5.00 /share | 11 Aug 2021 | 5,251.65 | 5,820.45 |
| 13 Aug 2021 | Dividend | ₹ 30.00 /share | 11 Aug 2021 | 5,251.65 | 5,820.45 |
| 19 Aug 2022 | Dividend | ₹ 35.00 /share | 18 Aug 2022 | 4,261.65 | 4,215.30 |
| 20 Feb 2022 | Dividend | ₹ 30.00 /share | 19 Sept 2022 | 4,277.45 | 4,346.40 |
| 11 Aug 2023 | Dividend | ₹ 5.00 /share | 11 Aug 2023 | 3,772.20 | 4,038.75 |
| 11 Aug 2023 | Dividend | ₹ 35.00 /share | 11 Aug 2023 | 3,772.20 | 4,038.75 |
| 21 Aug 2024 | Dividend | ₹ 35.00 /share | 21 Aug 2024 | 4,335.90 | 5,901.90 |
| 28 Aug 2024 |  Annual General Meeting | NA | 28 Aug 2024 | 5,842.95 | 5,862.80 |
| 28 Oct 2024 |  Quarterly Result Announcement | NA | 28 Oct 2024 | 5,673.00 | 5,308.70 |
| 31 Jan 2025 | Quarterly Result Announcement | NA | 31 Jan 2025 | 4,784.65 | 4,516.55 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 4,249.90 | 4,411.35 |
| 09 Jul 2025 | Dividend | ₹ 30.00 /share | 09 Jul 2025 | 4,411.35 | 5,851.00 |
| 09 Jul 2025 | Dividend | ₹ 35.00 /share | 09 Jul 2025 | 4,411.35 | 5,851.00 |
| 21 Jul 2025 | Annual General Meeting | NA | 21 Jul 2025 | 4,411.35 | 5,319.50 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 5,052.80 | 5,087.05 |
Announcements
Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.3 hours ago
3 hours agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025Aug 13, 2025
Aug 13, 2025Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30 2025 Held Today August 13 2025Aug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Aug 11, 2025Launch Of Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P. 20 - Valent (PCV20)Aug 11, 2025
Aug 11, 2025Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Aug 07, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJul 22, 2025
Jul 22, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJul 21, 2025
Jul 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 02, 2025
Jul 02, 2025Letter To Shareholders Providing The Weblink For Accessing The Annual Report.Jun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 30, 2025
Jun 30, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Business Responsibility and Sustainability Reporting (BRSR)Jun 29, 2025
Jun 29, 2025Reg. 34 (1) Annual Report.Jun 29, 2025
Jun 29, 2025Notice Of The 74Th Annual General Meeting Of The Company.Jun 29, 2025
Jun 29, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 23, 2025
May 23, 2025Appointment Of Cost And Secretarial AuditorMay 19, 2025
May 19, 2025Intimation Of Date Of Annual General MeetingMay 19, 2025
May 19, 2025Corporate Action-Board approves DividendMay 19, 2025
May 19, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 19, 2025
May 19, 2025Board Meeting Intimation for Board Meeting To Consider And Approve The Audited Financial Results For The Quarter And Financial Year Ended March 31 2025.May 13, 2025
May 13, 2025Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2Apr 29, 2025
Apr 29, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Apr 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Apr 01, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane And Sale Of
Structures And Buildings Constructed Thereon To Zoetis Pharmaceutical Research Private Mar 29, 2025
Mar 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 19, 2025
Mar 19, 2025Board Meeting Outcome for Marketing And Supply Agreement With Mylan Pharmaceuticals Private LimitedFeb 21, 2025
Feb 21, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 14, 2025
Feb 14, 2025Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Feb 05, 2025Receipt Of GST Order Levying Tax Demand And PenaltyFeb 05, 2025
Feb 05, 2025Receipt Of GST Order For A Tax Demand Interest And PenaltyFeb 04, 2025
Feb 04, 2025Levy Of Tax Demand And PenaltyFeb 03, 2025
Feb 03, 2025Integrated Filing (Financial)Feb 01, 2025
Feb 01, 2025Update On Transfer And Assignment Of PfizerS Unexpired Leasehold Rights In The Land Situated At Plot No. 16 Trans Thane Creek Industrial Area Turbhe Thane To Zoetis Pharmaceutical Research Private LimFeb 01, 2025
Feb 01, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 31, 2025
Jan 31, 2025Board Meeting Outcome for Outcome Of The Board Meeting- Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 31, 2025
Jan 31, 2025Board Meeting Intimation for Board Meeting To Consider And Take On Record The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Jan 24, 2025
Jan 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2025
Jan 14, 2025Closure of Trading WindowDec 30, 2024
Dec 30, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 17, 2024
Dec 17, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 11, 2024
Dec 11, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 03, 2024
Dec 03, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 19, 2024
Nov 19, 2024Announcement under Regulation 30 (LODR)-Change in ManagementNov 14, 2024
Nov 14, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 12, 2024
Nov 12, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateNov 10, 2024
Nov 10, 2024Mutual Fund Holdings
LIC MF Small Cap Fund Direct - Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
Bandhan Multi Cap Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth 
Aditya Birla Sun Life Pharma & Healthcare Fund Direct-Growth 
Samco Multi Asset Allocation Fund Direct-Growth 
UTI Healthcare Fund Direct-Growth 
Groww Value Fund Direct-Growth 
Baroda BNP Paribas Manufacturing Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Smallcap Fund Direct Plan-Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 45.98
ATR(14)
Less Volatile 122.61
STOCH(9,6)
Neutral 26.78
STOCH RSI(14)
Oversold 5.82
MACD(12,26)
Bearish -12.10
ADX(14)
Weak Trend 20.35
UO(9)
Bearish 48.65
ROC(12)
Downtrend And Accelerating -3.36
WillR(14)
Oversold -92.61
About Pfizer
Pfizer Limited is an Indian pharmaceutical company engaged in manufacturing, marketing, trading, and exporting pharmaceutical products. It has a manufacturing facility in Goa and works with contract manufacturers across India. The company offers a diverse portfolio of products including vaccines, anti-infectives, cardiac medications, pain relief, maternal nutrition, gastrointestinal treatments, contraceptives, anti-inflammatories, and respiratory medicines. Pfizer's key focus areas include vaccines, with Prevenar 13 for pneumococcal prevention, and inflammation and immunology treatments for chronic immune system diseases. The company has undergone several mergers, acquisitions, and divestments over the years, including the merger with Wyeth Limited in 2014 and the sale of certain established medicine brands to Mylan Pharmaceuticals in 2022.
Website
Chairperson NamePradip P Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
